News
10-12-2010, 09:50 PM
European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.
More... (http://www.news-medical.net/news/20101013/Combination-of-cetuximab-and-cisplatin-chemotherapy-benefits-women-with-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20101013/Combination-of-cetuximab-and-cisplatin-chemotherapy-benefits-women-with-triple-negative-breast-cancer.aspx)